EUVIMEDEUVIMED entdecken
Crossref

Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology

Stephen B Ma, Wendi Lin, Janine Campbell, Kerrie Clerici, Deborah White, David Yeung, Malgorzata Gorniak, Shaun Fleming, Chun Y Fong, Rishu Agarwal

Pathology · 2024-12 · 56 (7) · 982-992

DOI: 10.1016/j.pathol.2024.04.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology, 2024-12. Verfasst von Stephen B Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Austin Pathology, Heidelberg, Vic, Australia; Austin Health, Heidelberg, Vic, Australia. Electronic address: ma.stephen@icloud.com. Hauptthemen laut MEDLINE: Neoplasm, Residual, High-Throughput Nucleotide Sequencing, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualHigh-Throughput Nucleotide SequencingPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansRetrospective StudiesMaleAdultFemaleMiddle AgedChildAdolescentAustraliaYoung AdultAgedChild, PreschoolReceptors, Antigen, T-CellImmunoglobulin Heavy ChainsFlow Cytometry

Stichwörter der Autor:innen

Acute lymphoblastic leukaemiaT cell receptor gene rearrangementclonalitydisease monitoringimmunoglobulin gene rearrangementmeasurable residual diseasenext generation sequencing

Substanzen

Receptors, Antigen, T-CellImmunoglobulin Heavy Chains

Autor:innen und Institutionen

  • Austin Pathology, Heidelberg, Vic, Australia; Austin Health, Heidelberg, Vic, Australia. Electronic address: ma.stephen@icloud.com.
  • Austin Pathology, Heidelberg, Vic, Australia.
  • Royal Children's Hospital, Parkville, Vic, Australia.
  • South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia.
  • Alfred Health, Melbourne, Vic, Australia.
  • Alfred Health, Melbourne, Vic, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Vic, Australia.

Zitieren

APA

Ma, S. B., Lin, W., Campbell, J., Clerici, K., White, D., Yeung, D., Gorniak, M., Fleming, S., Fong, C. Y., & Agarwal, R. (2024). Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology. Pathology, 56(7), 982-992. https://doi.org/10.1016/j.pathol.2024.04.012

Vancouver

Ma SB, Lin W, Campbell J, Clerici K, White D, Yeung D, et al. Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology. Pathology. 2024;56(7):982-992. doi:10.1016/j.pathol.2024.04.012

BibTeX
@article{Ma2024,
  author = {Ma, Stephen B and Lin, Wendi and Campbell, Janine and Clerici, Kerrie and White, Deborah and Yeung, David and Gorniak, Malgorzata and Fleming, Shaun and Fong, Chun Y and Agarwal, Rishu},
  title = {Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology},
  journal = {Pathology},
  year = {2024},
  volume = {56},
  number = {7},
  pages = {982--992},
  doi = {10.1016/j.pathol.2024.04.012}
}
Kostenlos starten →